AGE-RELATED ISSUES OF THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEART FAILURE MIDDLE RANGE EJECTION FRACTION OF ELDERLY AND SENILE AGE AGAINST THE BACKGROUND OF PHARMACOTHERAPY

В статье рассмотрены вопросы изменения качества жизни лиц пожилого и старческого возраста с ХСН и промежуточной ФВ (ХСНпрФВ) в процессе длительной (12 мес) фармакотерапии. Были обследованы 377 больных, из них 129 - 45-59 лет (средний возраст), 128 - 60-74 лет (пожилой возраст), 120 - 75 лет и старше (старческого возраста). Диагноз устанавливали в соответствии с Рекомендациями по диагностике и лечению ХСН (2013, 2016 г.) Проведена оценка качества жизни по опроснику MLHFQ. Установлено улучшение качества жизни через 12 мес терапии во всех группах больных, но наиболее выраженные результаты получены в старческом возрасте. Максимальное снижение уровня тревоги наблюдали у мужчин средней возрастной категории, у женщин - в пожилом возрасте. В пожилом и старческом возрасте отмечено сопоставимое снижение баллов по шкале депрессии Цунга как у мужчин, так и у женщин. The article deals with the issues of changing the quality of life of elderly and senile people with chronic heart failure with middle range ejection fraction (CHFmrHF) during long-term (12 months) pharmacotherapy. 377 patients were examined, including 129 people aged 45 to 59 years (middle age), 128 people aged 60 to 74 years (elderly), and 120 people aged over 75 years (senile age). The diagnosis was made in accordance with the Recommendations for the diagnosis and treatment of CHF (2013, 2016). The quality of life was assessed according to the MLHFQ questionnaire. There was an improvement in the quality of life after 12 months of therapy in all groups of patients, but the most pronounced results were obtained in old age. The maximum decrease in the level of anxiety was observed in men in the middle age group, in women - in the elderly. In the elderly and senile age, there was a comparable decrease in the scores on the Zung depression scale in both men and women.

Download Full-text

Eff ect of nebivolol and carvedilol on the functional state of patients with chronic heart failure and preserved left ventricular ejection fraction

Clinical Medicine (Russian Journal) ◽

10.30629/0023-2149-2021-99-4-282-287 ◽

2021 ◽

Vol 99 (4) ◽

pp. 282-287

Author(s):

V. G. Tregubov ◽

P. V. Khilkevich ◽

I. Z. Shubitidze ◽

V. M. Pokrovskii ◽

N. V. Yukhnova

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Chronic Heart Failure ◽

Combination Therapy ◽

Ejection Fraction ◽

Functional State ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Group I

Objective. Compare the eff ect of combination therapy with nebivolol or carvedilol on the functional state of patients with chronic heart failure (CHF) and preserved ejection fraction (pEF) of the left ventricle (LV). Material and methods. The study involved 80 patients with diastolic CHF, who were randomized into two groups. In group I was appointed of nebivolol (7.7 ± 2.4 mg/day, n = 40), in group II — carvedilol (30.5 ± 8.7 mg/day, n = 40). As part of the combination therapy, quinapril was prescribed (13.7 ± 2.7 mg/day, n = 40 and 13.5 ± 2.6 mg/day, n = 40), and if indicated — atorvastatin (15.3 ± 4.6 mg/day, n = 17 and 16.2 ± 5.2 mg/day, n = 17) and acetylsalicylic acid in the intestinal soluble shell (96.4 ± 13.4 mg/day, n = 14 and 93.8 ± 13.3 mg/day, n = 13), respectively. Initially and after 6 months of therapy were carried out: quantitative assessment of regulatory-adaptive status (RAS) (by means of a sample of cardiac-respiratory synchronism), echocardioscopy, treadmill test, test with a six-minute walk, subjective assessment of quality of life, determination of the level of the N-terminal fragment of the brain natriuretic peptide in blood plasma, daily monitoring of blood pressure. Results. Both schemes of combined therapy comparably improved the structural and functional state of the heart, controlled arterial hypertension. In comparison with carvedilol, nebivolol diff ered positive eff ect on the RAS, more increased tolerance to physical activity and improved quality of life. Conclusion. In patients with CHF pEF LV in combination therapy, the use of nebivolol, in comparison with carvedilol, may be preferable due to the more pronounced positive eff ect on the functional state.

Download Full-text

Changes in quality of life after discharge from hospital in the elderly patients with acute worse of chronic heart failure

Journal of the Japanese Society of Intensive Care Medicine ◽

10.3918/jsicm.12.417 ◽

2005 ◽

Vol 12 (4) ◽

pp. 417-418

Author(s):

Kenzo Shibayama ◽

Naomi Kotera ◽

Natsuki Nakayama ◽

Yukari Aoyama ◽

Chie Yamada ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Chronic Heart Failure ◽

Elderly Patients ◽

The Elderly ◽

Discharge From Hospital

Download Full-text

The elderly liver transplant recipients: anxiety, depression, fatigue and life satisfaction

Zeitschrift für Gastroenterologie ◽

10.1055/s-0043-102580 ◽

2017 ◽

Vol 55 (06) ◽

pp. 557-563 ◽

Cited By ~ 2

Author(s):

Felix Krenzien ◽

Nicco Krezdorn ◽

Mehmet Morgül ◽

Georg Wiltberger ◽

Georgi Atanasov ◽

...

Keyword(s):

Quality Of Life ◽

Life Satisfaction ◽

Depression Scale ◽

The Elderly ◽

Poor Quality ◽

Age Related ◽

Related Quality ◽

Health Related ◽

Anxiety Depression

Abstract Introduction Older patients are neglected in clinical trials and are likely to be excluded from liver transplantation (LT). The aim of this study was to assess fatigue, anxiety, depression, and health-related quality of life (HRQoL) in elderly LT recipients. Methods Questionnaires were mailed to patients who underwent LT between 1993 and 2013. Three groups were created: patients ≥ 70, 60 – 69, and < 60 years old. Mental-health status, life satisfaction, and fatigue were assessed using, respectively, the Hospital Anxiety and Depression Scale (HADS), Questions on Life Satisfaction (FLZ-M), and the Multidimensional Fatigue Inventory (MFI-20). Results In total, 276 eligible questionnaires (40.1 %) were received out of 689 patients with a history of LT. No age-related differences were found with regard to anxiety or depression in the study sample. Patients ≥ 70 years old had significantly better life satisfaction in regards to income (p = 0.003) and work (p = 0.005) compared to patients < 60 years. The overall fatigue scores were the highest in patients < 60 years (52.7, SD = 15.8) and ≥ 70 years (52.7, SD = 17.7) compared to patients 60 – 69 years old (48.2, SD = 17.3, p = 0.037). Discussion Advanced age alone should not be considered a contraindication for LT due to potentially poor quality of life outcomes.

Download Full-text

Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure

Kardiologiia ◽

10.18087/cardio.2021.7.n1649 ◽

2021 ◽

Vol 61 (7) ◽

pp. 22-27

Author(s):

S. N. Tereschenko ◽

N. B. Perepech ◽

I. A. Cheremisina ◽

V. N. Belov ◽

Y. A. Vollis ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Chronic Heart Failure ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction

Aim Improvement of quality of life is one of the most important goals for the treatment of patients with chronic heart failure (CHF). This study searched for ways to increase the efficiency of CHF treatment based on parameters of quality of life in CHF patients during and after the treatment with exogenous phosphocreatine (EP).Material and methods The effect of a single course of EP treatment on quality of life of patients with functional class (FC) II-IV CHF with reduced or mid-range left ventricular ejection fraction was studied as a part of the all-Russia prospective observational study BYHEART. The presence of FC II-IV CHF and a left ventricular ejection fraction <50 % were confirmed by results of 6-min walk test (6MWT) and findings of echocardiography after stabilization of the background therapy.Results An interim data analysis showed that the course of EP treatment was associated with a significant improvement of quality-of-life indexes as determined by the Minnesota Living with Heart Failure Questionnaire (LHFQ) total score. These indexes significantly increased and remained at a satisfactory level for 6 mos. following completion of the treatment course. Also, the treatment significantly beneficially influenced the clinical condition of patients (heart failure severity scale), results of 6MWT, and the increase in left ventricular ejection fraction.Conclusion The conclusions based on results of the interim analysis should be confirmed by results of the completed study. Complete results are planned to be published in 2022.

Download Full-text

Pentoxyphylline: possibilities to reduce manifestations of chronic heart failure with preserved left ventricular ejection fraction in elderly

Zaporozhye Medical Journal ◽

10.14739/2310-1210.2021.1.224839 ◽

2021 ◽

Vol 23 (1) ◽

pp. 24-31

Author(s):

V. B. Shatylo ◽

L. A. Bodretska ◽

I. S. Shapovalenko ◽

H. P. Voinarovska ◽

Zh. S. Butynets

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Chronic Heart Failure ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction

The aim: to study the effect of add-on pentoxifylline therapy on the structural and functional indicators of the heart state, endothelial function, quality of life and physical abilities in patients with chronic heart failure with preserved left ventricular ejection fraction. Materials and methods. The indicators of the structural and functional state of the heart, endothelial function, quality of life and physical abilities of patients older than 60 years, who were followed-up in the Department of Cardiology of the State Institution “D. F. Chebotarev Institute of Gerontology of the NAMS of Ukraine”, based on 67 case histories, 37 of them were prescribed pentoxifylline as add-on therapy to the standard therapeutic regimen. Statistical data were calculated using modern application packages, in particular SPSS v.22, Statistica 7.0, MedCalc statical software v.11.5.0.0. The significance level was assessed using paired and unpaired Student's t-test with Bonferroni corrections, and the correlation and two-way analysis of variance were performed. Results. A significant additional effect of pentoxifylline treatment on the indicators of maximum blood flow in the forearm microvessels in response to the reactive hyperemia test, which characterizes the ability of the microvessel endothelium to synthesize relaxation factors, was detected. Patients who additionally received pentoxifylline showed significantly better indicators of left ventricular myocardial relaxation and reduction of hypertrophy than those on the standard therapy. There was a significant increase in walking distance in the third year of treatment in the patients who additionally received pentoxifylline. There was no difference in the impact on the quality of life of the patients. Conclusions. The addition of pentoxifylline to the standard therapy in patients with chronic heart failure with preserved left ventricular ejection fraction significantly reduces myocardial hypertrophy, improves diastolic relaxation, increases volumetric blood flow velocity in microvessels mediating reactive hyperemia, which may contribute to further stabilizing the clinical course of the disease and increasing 6-minute walking distance. The presented data are an additional evidence of pathogenetically reasonable therapy with pentoxifylline in patients with chronic heart failure with preserved left ventricular ejection fraction, which allows us to consider this drug as potentially promising for the routine treatment of such patients.

Download Full-text

Experience in the use of angiotensin receptor neprilysin inhibition in patients with chronic heart failure and chronic obstructive pulmonary disease

Vestnik of Russian military medical Academy ◽

10.17816/brmma25971 ◽

2020 ◽

Vol 22 (1) ◽

pp. 76-80

Author(s):

O A Kalimulin ◽

A V Koltsov ◽

V V Tyrenko ◽

S G Bologov ◽

V I Odin ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Chronic Obstructive Pulmonary Disease ◽

Chronic Heart Failure ◽

Ejection Fraction ◽

Pulmonary Disease ◽

Chronic Obstructive ◽

Angiotensin Receptor ◽

Obstructive Pulmonary Disease

The results of evaluating the effectiveness of the use of an angiotensin receptor-neprilysin inhibitor (valsartan / sacubitrile) in addition to standard therapy in comorbid patients suffering from chronic heart failure and chronic obstructive pulmonary disease are presented. It was revealed that the combination of valsartan / sacubitrile has a more pronounced therapeutic effect than the separate use of valsartan. At the same time, the level of the N-terminal cerebral natriuretic peptide decreases, especially in patients with a left ventricular ejection fraction of less than 40%, which indicates the effect on the pathogenetic mechanisms associated with the formation and progression of chronic heart failure. The effectiveness of the recommended combination of valsartan / sakubitrile is confirmed by a significant increase in the ejection fraction of the left ventricle of patients suffering from chronic heart failure, which significantly affects the increase in exercise tolerance and improving the quality of life. Improving the quality of life is confirmed by the positive dynamics of the «symptoms», «activity» blocks of the questionnaire for patients suffering from respiratory diseases, St. George’s hospital and «mobility», «usual daily activities» of the quality of life questionnaire, which also shows the advantage of using valsartan / sakubitril and increases patient commitment to prescribed therapy. A decrease in the cavity of the left atrium and a decrease in pressure in the pulmonary artery indicates not only an improvement in the function of the left chambers of the heart, but also of the right ventricle.

Download Full-text